Bundamedik Tbk PT
IDX:BMHS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
240
378
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bundamedik Tbk PT
Bundamedik Tbk PT
Cost of Revenue
Bundamedik Tbk PT
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bundamedik Tbk PT
IDX:BMHS
|
Cost of Revenue
-Rp792.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Siloam International Hospitals Tbk PT
IDX:SILO
|
Cost of Revenue
-Rp7.2T
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-13%
|
|
|
Medikaloka Hermina Tbk PT
IDX:HEAL
|
Cost of Revenue
-Rp4.2T
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sejahteraraya Anugrahjaya Tbk PT
IDX:SRAJ
|
Cost of Revenue
-Rp2T
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-24%
|
|
|
Mitra Keluarga Karyasehat Tbk PT
IDX:MIKA
|
Cost of Revenue
-Rp2.2T
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
F
|
Famon Awal Bros Sedaya Tbk PT
IDX:PRAY
|
Cost of Revenue
-Rp1.3T
|
CAGR 3-Years
-19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bundamedik Tbk PT
Glance View
PT Bundamedik Tbk is a holding company, with engages in the provision of healthcare and medical technology services. The company is headquartered in Jakarta Pusat, Dki Jakarta and currently employs 1,285 full-time employees. The company went IPO on 2021-07-06. The firm is engaged in private hospital activities, private polyclinic activities, and other hospital activities. The Company’s also offers other hospital activities, such as healthcare services activities performed by paramedics and health support service activities. The firm operates two general clinics in Jakarta and Bekasi that offer services, such as obstetrics and gynecology specialist poly, child specialist poly, skin and aesthetic poly, dental and oral poly, general poly, medical check-ups, internal medicine poly, poly nutrition, and pharmacy. The company offers a range of services, such as mother and child services, outpatient services, inpatient services, in vitro fertilization (IVF) services, and clinical laboratory services. The firm operates approximately two maternal and child hospitals, three general hospitals, 10 IVF clinics, 14 laboratories and various other supporting business activities.
See Also
What is Bundamedik Tbk PT's Cost of Revenue?
Cost of Revenue
-792.4B
IDR
Based on the financial report for Dec 31, 2023, Bundamedik Tbk PT's Cost of Revenue amounts to -792.4B IDR.
What is Bundamedik Tbk PT's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-12%
Over the last year, the Cost of Revenue growth was 11%. The average annual Cost of Revenue growth rates for Bundamedik Tbk PT have been -7% over the past three years , -12% over the past five years .
You don't have any saved screeners yet
